key: cord-1043363-btizbwkl
authors: Sionov, Ronit Vogt; Steinberg, Doron
title: Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles
date: 2022-03-09
journal: Biomedicines
DOI: 10.3390/biomedicines10030631
sha: bf53fcc7c742dcac9208651cf57f3d7672addd0b
doc_id: 1043363
cord_uid: btizbwkl

Antibiotic resistance has become an increasing challenge in the treatment of various infectious diseases, especially those associated with biofilm formation on biotic and abiotic materials. There is an urgent need for new treatment protocols that can also target biofilm-embedded bacteria. Many secondary metabolites of plants possess anti-bacterial activities, and especially the phytocannabinoids of the Cannabis sativa L. varieties have reached a renaissance and attracted much attention for their anti-microbial and anti-biofilm activities at concentrations below the cytotoxic threshold on normal mammalian cells. Accordingly, many synthetic cannabinoids have been designed with the intention to increase the specificity and selectivity of the compounds. The structurally unrelated endocannabinoids have also been found to have anti-microbial and anti-biofilm activities. Recent data suggest for a mutual communication between the endocannabinoid system and the gut microbiota. The present review focuses on the anti-microbial activities of phytocannabinoids and endocannabinoids integrated with some selected issues of their many physiological and pharmacological activities.

Plant medicine has often been used for the treatment of diverse diseases, including bacterial and fungal infections [1] [2] [3] [4] [5] [6] [7] [8] . The plants produce a series of secondary metabolites, many of which have pharmacological as well as anti-microbial activities [4] [5] [6] [9] [10] [11] . Evolutionarily, plants have developed various anti-microbial mechanisms to protect them from infectious diseases [11] . Usually, these include the production of compounds that have anti-biofilm and bacteriostatic activities rather than biocidal effect [11] . Compounds with anti-biofilm activities are believed not to induce resistance mechanisms in the microbes, since they target processes not essential for their survival. In contrast, compounds with bactericidal activity might lead to the development of resistance mechanisms in the microbe as part of the bacterial fitness adaptation process with increased probability of developing microbial plant infections.

Cannabis sativa L. subspecies are plants that contain a large variety of secondary metabolites, including phytocannabinoids, terpenoids and flavonoids, which have profound anti-microbial activities, in addition to possessing anti-inflammatory, anti-oxidative and neuromodulatory properties [12] [13] [14] . In mammalians, the phytocannabinoids interact with the same receptors (e.g., cannabinoid receptors CB1 and CB2) as the endocannabinoids [15] , which are endogenous substances with anti-microbial, anti-inflammatory and neuromodulatory activities [16] [17] [18] [19] [20] [21] [22] [23] [24] . While much is known about the cannabinoid targets in mammalians, so far, little is known about the microbial targets of these compounds. It is likely that these compounds also interact with specific targets in the microbes. The present 2.1. Anti-Microbial Activity of Cannabis sativa L. Extracts Z. Krejčí, in the 1950s, observed that Cannabis has antibiotic activity and introduced it to the clinics in Czechoslovakia [55], a practice that was discontinued in 1990 [33] . The first compound identified by Krejčí with antibiotic activity was named cannabidiolic acid (CBDA) [56, 57] . From then on, several other Cannabis components with antibiotic activities have been isolated and characterized [48, [58] [59] [60] [61] [62] [63] , which will be further discussed below. In 1956, L. Ferenczy published a paper documenting that plant seeds from various plant species, including those from Cannabis sativa, exhibited antibacterial activity, especially against Gram-positive bacteria [64] . Wasim et al. [65] documented that both ethanolic and petroleum ether extracts of Cannabis sativa leaves showed anti-microbial activity against Bacillus subtilis, Staphylococcus aureus, Micrococcus flavus, Bordetella bronchiseptica, Proteus vulgaris, Aspergillus niger, and Candida albicans. Ali et al. [66] observed that the oil of the seeds of Cannabis sativa exerted pronounced anti-bacterial activity against Bacillus subtilis and Staphylococcus aureus, with moderate activity against Escherichia coli and Pseudomonas aeruginosa, without any activity against Aspergillus niger and Candida albicans. The petroleum ether extract of the whole plant showed high anti-bacterial activity against Bacillus subtilis and Staphylococcus aureus, moderate activity against Escherichia coli, while no activity against Pseudomonas aeruginosa or the tested fungi [66] . Thus, the extraction method and the source affect the composition of the anti-microbial content and the spectrum of responding microbes.

Novak et al. [67] analyzed the anti-bacterial effect of essential oils prepared from five different cultivars of Cannabis sativa L. These essential oils contained, among others, α-pinene, myrcene, trans-β-ocimene, α-terpinolene, trans-caryophyllene, and α-humulene, but undetectable levels of ∆ 9 -THC and very poor levels of other cannabinoids [67] . They observed differences in the anti-bacterial activity between the various cultivars. All five essential oils showed anti-bacterial activity against Acinetobacter calcoaceticus, Beneckea natriegens, Brochothrix thermosphacta and Staphylococcus aureus [67] . Only one of the five essential oils had an anti-bacterial effect on Escherichia coli, while none affected Enterobacter aerogenes, Klebsiella pneumoniae, Proteus vulgaris, Salmonella pullorum, Serratia marcescens, or Streptococcus faecalis [67] .

Nissen et al. [34] observed that essential oils of Cannabis sativa L., prepared from 50-70% of seed maturity, showed anti-bacterial activity against the Gram-positive bacteria Enterococcus faecium and Streptococcus salivarius at less than 1% (v/v) but were unable to inhibit the growth of the yeast Saccharomyces cerevisiae. Zengin et al. [68] found that essential oils distilled from leaves, inflorescences, and thinner stems of the hemp plant showed antioxidative properties and had significant anti-bacterial activity against clinical Helicobacter pylori strains (MIC = 16-64 µg/mL), with lower activity against clinical Staphylococcus aureus isolates (MIC = 8 mg/mL) and no significant activity against Candida spp. and Malassezia spp. The minimum bacterial biofilm inhibitory concentration (MBIC) of the hemp essential oil against Helicobacter pyroli was similar to the MIC [68] . The hemp essential oil showed cytotoxicity against human breast cancer, cholangiocarcinoma, and colon carcinoma cell lines at 50-75 µg/mL, while 250 µg/mL was required to inhibit the cell proliferation of a nonmalignant cholangiocyte cell line [68] . The LD 50 of hemp essential oil against larvae of Galleria mellonella was found to be 1.56 mg/mL, which is much higher than the antibacterial activity against Helicobacter pyroli, but lower than that found to be active against Staphylococcus aureus strains [68] .

The Cannabis sativa L. plants produce more than 560 chemicals, including at least 144 cannabinoids and 200 terpenoids, as well as flavonoids and polyunsaturated fatty acids [15, 33, 34, 42, 63, 67, 72, 73, [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] . The most common phytocannabinoids are ∆ 9 -tetrahy drocannabinol (∆ 9 -THC) and cannabidiol (CBD), which are the neutral homologs of tetrahydrocannabinolic acid (THCA) and cannabidiol acid (CBDA), respectively [108] . The phytocannabinoids are terpenophenolic compounds containing a resorcinyl core with a parapositioned isoprenyl, alkyl, or aralkyl side chain [39, 40] (Figure 1 ). The tetrahydrobenzochromen ring is quite unique to the genus Cannabis, although a related compound has been found in the liverwort Radula marginata [109] , and cannabigerol (CBG) and its corresponding acid have been isolated from Helichrysum umbraculigerum [110] .

Apart from exerting anti-microbial activities, which will be discussed in more detail below (Section 3.3), phytocannabinoids modulate several physiological and pathophysiological processes in humans and other mammalians, making them potential therapeutic drugs in various settings [12] [13] [14] 31, [111] [112] [113] [114] [115] . Among others, these compounds have been shown to have anti-inflammatory, anti-oxidative, anti-nausea, anti-nociceptive, anti-convulsant, anti-neoplastic, anxiolytic, and neuroprotective properties [14, 111, 112, [114] [115] [116] [117] . Cannabinoids also affect cognition, such as learning and memory, consciousness, and emotion, including anxiety and depression [118, 119] .

Some cannabinoid-based drugs (e.g., Marinol, Syndros, Cesamet, Sativex, and Epidiolex) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, Parkinson's disease, spasticity associated with multiple sclerosis, neuropathic pain, mental illnesses, chemotherapy-induced nausea, and AIDS wasting syndrome [117, [120] [121] [122] . Marinol and Syndros contain the (-)-trans-∆ 9 -THC dronabinol; Cesamet contains the synthetic cannabinoid nabilone that shows structural similarities to ∆ 9 -THC; and Epidiolex contains CBD. Sativex is produced from a Cannabis-derived extract that is composed of approximately equal quantities of ∆ 9 -THC and CBD. A major concern is the production of many psychotropic synthetic cannabinoids distributed on the illicit market, which poses a potential health treat due to their high potency and toxicity [123] .

Biomedicines 2022, 10, x FOR PEER REVIEW 6 of 50 the phosphoinositide-3 kinase (PI3K)/Akt signaling pathways and the mammalian target of rapamycin (mTOR) [126] [127] [128] [129] [130] [131] [132] [133] [134] . 

The effects of phytocannabinoids on humans and other mammalians are partly mediated by the G i/o protein-coupled CB1 (encoded by the CNR1 gene) and CB2 (encoded by the CNR2 gene) cannabinoid receptors that consist of seven transmembrane domains [124] [125] [126] .

The stimulation of these receptors leads to the inhibition of adenylyl cyclase with consequent reduction in the intracellular cAMP levels, activation of potassium channels, activation of mitogen-activated protein kinases (MAPKs) such as the extracellular signalregulated kinase (ERK) and c-Jun N-terminal kinase (JNK), as well as activation of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathways and the mammalian target of rapamycin (mTOR) [126] [127] [128] [129] [130] [131] [132] [133] [134] .

The CB1 and CB2 receptors also recognize the endogenous arachidonic acid-derived endocannabinoids, such as N-Arachidonoylethanolamine (anandamide; AEA) and 2-arach idonoylglycerol (2-AG) [134] [135] [136] . Both CB1 and CB2 are expressed in various cells in the brain and in peripheral tissues [137] . CB1 is especially expressed at high levels in the neocortex, hippocampus, basal ganglia, cerebellum, and brainstem, but it is also found in peripheral nerve terminals and some tissues, such as the vascular endothelium, spleen, testis, and eye [137] . CB2 is predominantly found in cells of the immune system, and in the central nervous system, it is primarily localized to microglia and tissue macrophages [137] .

The CB1 receptor regulates the balance between excitatory and inhibitory neuronal activity. The psychoactive effect is believed to be mediated through the CB1 receptor in the brain, whereas the immunomodulatory effects are anticipated to be mediated via the CB2 receptor expressed on immune cells [138, 139] . In addition, CB1 signaling affects metabolism and is involved in maintaining whole body energy homeostasis by increasing appetite and stimulating feeding [140] . Many efforts have been made to develop CB2 specific agonists at an attempt to achieve anti-inflammatory actions without psychotropic adverse effects [13, [141] [142] [143] . The sesquiterpene (E)-β-caryophyllene produced by Cannabis as well as other plants, including oregano (Origanum vulgare L.), cinnamon (Cinnamomum spp.), and black pepper (Piper nigrum L.), was found to bind selectively to the CB2 receptor and exert anti-inflammatory activities [144] [145] [146] [147] .

Other cannabinoid receptors include transient receptor potential vanilloid 1 (TRPV1), the G-protein-coupled receptors GPR18 and GPR55, and peroxisome proliferator activated receptors (PPARs) [126, 134, [148] [149] [150] [151] [152] . The anti-nociceptive effect of Cannabis sativa extracts was found to be mediated by the binding of CBD to TRPV1 [153] . A study by Ibrahim et al. [154] showed that activation of the CB2 receptor by its agonist AM1241 stimulated the release of beta-endorphin from keratinocytes, which, in turn, acted on neuronal µopoid receptors to inhibit nociception. The Cannabis sativa extract containing multiple cannabinoids, terpenes, and flavonoids had stronger anti-nociceptive effect than a single cannabinoid given alone [153] , suggesting an "entourage" effect of the various Cannabiscontaining compounds [74] .

The CB1 and CB2 can form receptor heteromers [155] . The activity of the receptor heteromer is affected by the agonists and antagonists that bind to each of them. A CB1 antagonist can block the effect of a CB2 agonist and vice versa; a CB2 antagonist can block the effect of a CB1 receptor agonist [155] . CB1 has also been shown to form heteromers with dopamine and adenosine receptors [156] [157] [158] , AT1 angiotensin receptor [159] , µ 1 -opoid receptor [160, 161] , and OX1 orexin A receptor [162] . The many interacting partners put CB1 signaling under strict regulation.

3.2.1. ∆ 9 -Tetrahydrocannibinol (∆ 9 -THC) ∆ 9 -THC binds to CB1 and CB2 receptors at a more or less equal affinity [138, 163, 164] . It also acts on CB1-CB2 receptor heterodimers [165] . ∆ 9 -THC is well known for its psychomimetic activities that are exerted by its binding to CB1 receptor in the brain, resulting in a calm and sedated mental state [49] . Besides euphoria, ∆ 9 -THC is an appetite stimulator [166] . Oral ∆ 9 -THC (Dronabinol, Marinol) and its synthetic nabilone (Cesamet) have been used for the treatment of nausea and appetite stimulation for people undergoing chemotherapy and for AIDS wasting syndrome [167, 168] . The activation of CB1 by ∆ 9 -THC is believed to mediate its anti-nausea and anti-emetic effects [169] . Sativex, which contains Biomedicines 2022, 10, 631 8 of 48 a combination of ∆ 9 -THC and CBD, has been used for relief of neuropathic pain in multiple sclerosis [170] .

The non-psychotropic cannabidiol (CBD) shows low affinity to the CB1 and CB2 receptors [135] and can exert antagonistic modulatory actions on these receptors [138, 171] . CBD can also activate the TRPV1 channel, serotonin 1A (5-HT 1A ) receptors, and opioid receptors [24, 172] . CBD has anti-inflammatory, anti-oxidative, anti-epileptic, analgesic, anti-neoplastic, sedative, neuroprotective, and anti-anxiety activities [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] . Moreover, CBD inhibits sebocyte lipogenesis by activating the TRPV4 ion channel that interferes with the pro-lipogenic ERK1/2 MAPK pathway [189] .

The neuroprotective activity of CBD has been attributed in part to its anti-oxidative activity [190, 191] . Based on its immunomodulatory activities, CBD has been implicated in the treatment of various autoimmune diseases [14, 21] , and its anti-nociceptive activity was found to be beneficial in relieving chronic pain [192] . In addition, CBD has potential uses in psychiatry due to its neuromodulatory activities in the brain that control recognition, emotional and behavioral responses [111, 193, 194] . CBD has especially been reported to have therapeutic effect for psychopathological conditions, such as substance use disorders, chronic psychosis, and anxiety [193] . CBD has been shown to be well tolerated in humans at concentrations as high as 3500-6000 mg/day [195] [196] [197] , and the FDA-approved CBD (marketed as Epidiolex) is indicated for preventing epileptic seizures in Lennox-Gastaut syndrome and Dravet syndrome in children [198] .

In experimental mice and rat models, CBD has been shown to have immunosuppressive activities [181] , which are partly due to inhibition of TNFα production [199, 200] and induction of myeloid-derived suppressor cells (MDSCs) [201] . CBD alleviated the symptoms of experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis and prevented the onset of autoimmune diabetes in experimental murine models [199, 200, 202] . In mice, the anti-inflammatory activity of CBD was found to have a bell-shaped dose-response with an optimal dose of 5 mg/kg [203] . The use of a standardized extract from a CBD-rich, ∆ 9 -THC low Cannabis indica cultivar overcame this bell-shaped dose-response, suggesting a synergistic effect among the different compounds of the Cannabis extract [199] .

CBG is another non-psychoactive Cannabis component that is produced at elevated levels in some industrial hemps [204] [205] [206] . It binds to both CB1 and CB2 receptors and modulates the signaling through these receptors, as well as the CB1-CB2 receptor heteromer, at concentrations as low as 0.1-1 µM [207] . CBG competes with the binding of [ 3 H]-WIN-55,212-2 to CB2, but not to CB1 [207] . Further studies suggest that CBG is a partial agonist of CB1 and CB2 [207] [208] [209] . CBG activates TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, 5-HT 1a receptor, α2-adrenergic receptor, and PPARγ, while being a TRPM8 antagonist [210] [211] [212] [213] [214] [215] . CBG has anti-inflammatory, anti-oxidative, and anti-nociceptive activities [117, 209, 213, 216] . The anti-inflammatory property is thought to be achieved by modulating the CB2 receptor, TRP channels, and PPARγ, and by inhibiting cyclooxygenase 1 and 2 (COX-1/2) [210, 211, 217] , while the analgesic effect of CBG is thought to be mediated through the α2-adrenergic receptor [211] . CBG has been shown to have potential beneficial effects in treating inflammatory bowel disease and neurological disorders, such as Huntington's disease, Parkinson's disease, and multiple sclerosis [213, 215, 216, 218, 219] .

CBC is a non-psychoactive phytocannabinoid that activates the CB1 and CB2 receptors, resulting in decreased intracellular levels of cAMP [209] . CBC also activates the TRPA1, TRPV3, and TRPV4 channels [210] . CBC has anti-inflammatory, anti-nociceptive, and neuroprotective activities [220] [221] [222] [223] [224] [225] . CBC reduces the activity of both the ON and OFF Biomedicines 2022, 10, 631 9 of 48 neurons in the rostral ventromedial medulla (RVM) and elevates the endocannabinoid levels in the ventrolateral periaqueductal gray matter [221] . The anti-nociceptive activity of CBC is mediated by the adenosine A1 and TRPA1 receptors [221] . CBC increases the viability of neural stem progenitor cells through activation of the adenosine A1 receptor [224] . Moreover, it has been shown to suppress reactive astrocytes, thus offering a protective effect against neuro-inflammation and Alzheimer's disease [225] . CBC had anti-convulsant properties in a mouse model of Dravet syndrome [226] , and it exhibited cytotoxic activity against some carcinoma cells [227, 228] .

CBDA has low affinity for both CB1 and CB2 receptors, with moderate inhibition of adenylyl cyclase activity [209, 229] , and functions as an allosteric regulator on the 5-HT 1A receptor, resulting in anti-emetic effects [230] [231] [232] [233] . In addition, it activates PPARα and PPARγ [212] . CBDA shows anti-nociceptive and anti-inflammatory effects that are in part mediated by COX-2 inhibition and activation of the TRPV1 channel [217, 234, 235] . CBDA has anxiolytic and anti-convulsant effects in animal models [236] [237] [238] .

3.2.6. Cannabigerolic Acid (CBGA) CBGA displays low affinity for both CB1 and CB2 receptors but causes a similar decrease in intracellular cAMP levels as ∆ 9 -THC [229] . Since CBGA can activate PPARs [212] , it is expected to affect lipid metabolism [117] . A Cannabis sativa cultivar containing high levels of CBG and CBGA inhibited the activity of the aldose reductase enzyme, which catalyzes the reduction of glucose to sorbitol [239] . Since the aldose reductase level is increased at high glucose levels and has been implicated in the development of neuropathy, nephropathy, retinopathy, and cataract in diabetes, CBGA has been suggested as a potential drug in preventing diabetic complications [239] . In the Scn1a +/− mouse model of Dravet syndrome, CBGA was found to have an anti-convulsant effect that was mediated by its interaction with the GPR55, TRPV1, and GABA A receptors [240] .

CBN is formed during the degradation of ∆ 9 -THC and has a lower binding affinity to CB1 and CB2 receptors than ∆ 9 -THC [117] . CBN is an agonist of the TRPV1, TRPV2, TRPV3, TRPV4, and TRPA1 cation channels [210] . CBN is a non-psychotropic phytocannabinoid with analgesic and anti-inflammatory properties and acts as an appetite stimulant [117] . CBN has neuroprotective activity that is associated with its anti-oxidative actions, trophic support, and elimination of intraneuronal β-amyloid in neuronal cells [241] . CBN preserves mitochondrial functions, such as redox regulation, calcium uptake, mitochondrial membrane potential, and bioenergetics [242] . CBN promotes endogenous antioxidant defense mechanisms and triggers AMP-activated protein kinase (AMPK) signaling pathways [242] .

Several phytocannabinoids have been shown to have anti-bacterial activities, especially on Gram-positive bacteria, including various antibiotic-resistant strains [58, 59, 62, 63, 101, 220, [243] [244] [245] [246] [247] (Table 1) . Phytocannabinoids have been shown to exert both bactericidal and bacteriostatic effects [61, 62, 244, 247] . Most of the studies have analyzed the half maximal inhibitory concentration (IC 50 ) or minimum inhibitory concentration (MIC) for each of the compounds against different bacterial species, fungi, and protozoa, while only a few studies have looked at the underlying mechanisms [61, 243, 244, [247] [248] [249] [250] (Figure 2 ). Table 1 . Examples of Cannabis sativa constituents that have been documented to possess anti-bacterial, anti-fungal, and/or anti-protozoal activities *.

Anti-Microbial Activity Reference 

* BIC 50 = The test concentration that prevents 50% biofilm formation compared to control cells. IC 50 = The test concentration that causes 50% growth inhibition in comparison to control cells. MBEC = Minimum biofilm eradication concentration is the lowest concentration that completely eradicates preformed biofilm. MBIC = Minimum biofilm inhibitory concentration is the lowest concentration that is required to completely prevent any biofilm formation. MIC = Minimum inhibitory concentration is the lowest concentration that completely inhibits bacterial growth (when no turbidity is observed).

The minimum inhibitory concentration (MIC) of ∆ 9 -THC and CBD on various Staphylococcus aureus strains, including MRSA and Streptococci species (e.g., Streptococcus pyogenes and Streptococcus. faecalis) was found to be in the range of 1-5 µg/mL [58, 62, 245, 246] . There was no significant difference between the anti-bacterial effect of ∆ 9 -THC and CBD [58, 245, 246] . The anti-microbial effect was attenuated by the presence of either serum or blood, suggesting that serum components can bind the compounds and prevent them from acting on the microorganisms [245] . CBG shows anti-bacterial activity against Gram-positive bacteria, including MSSA, MRSA, and the oral cariogenic Streptococcus mutans at low concentrations similar to CBD [58, 61, 244, 247] . CBC and CBDA showed a MIC of 1-2 µg/mL against Staphylococcus aureus and Staphylococcus epidermidis [62, 220] . In these studies, CBDA was less active than CBD [62] . Cannabichromenic acid (CBCA) caused a rapid reduction in the colony-forming units (CFUs) of a clinical MRSA isolate both during the exponential and stationary growth phase, suggesting a bactericidal activity that is independent of the metabolic state of the bacteria [254] . None of the phytocannabinoids had any significant anti-bacterial activity against Gram-negative bacteria, such as Escherichia coli, Salmonella typhi, Pseudomonas aeruginosa, and Proteus vulgaris [61, 62, 220, 245, 247] . This might be due to the inability of these compounds to penetrate the outer membrane of the Gram-negative bacteria [61] , or the outer membrane protects the bacteria from cell death caused by damage to the inner membrane.

Interestingly, CBD and CBG could act on some Gram-negative bacteria (e.g., Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa) if the outer membrane was permeabilized with the LPS-binding antibiotic polymyxin B [61, 247] . It was shown that an Escherichia coli ΔbamBΔtolC deletion strain that renders the bacteria hyperpermeable to many small molecules was sensitive to CBG with a MIC of 4 μg/mL, which is in contrast to the parental Escherichia coli wild-type strain that showed a MIC above 128 μg/mL [61] . Similarly, a lipo-oligosaccharide-deficient Acinetobacter baumannii strain became sensitive to CBG with a MIC of 0.5 μg/mL compared to the parental strain showing a MIC of 64 μg/mL [61] . 

Interestingly, CBD and CBG could act on some Gram-negative bacteria (e.g., Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa) if the outer membrane was permeabilized with the LPS-binding antibiotic polymyxin B [61, 247] . It was shown that an Escherichia coli ∆bamB∆tolC deletion strain that renders the bacteria hyperpermeable to many small molecules was sensitive to CBG with a MIC of 4 µg/mL, which is in contrast to the parental Escherichia coli wild-type strain that showed a MIC above 128 µg/mL [61] . Similarly, a lipo-oligosaccharide-deficient Acinetobacter baumannii strain became sensitive to CBG with a MIC of 0.5 µg/mL compared to the parental strain showing a MIC of 64 µg/mL [61] .

No synergistic or antagonistic effects of CBD were observed on MRSA strain USA300 when combined with different conventional antibiotics, such as clindamycin, ofloxacin, meropenem, tobramycin, methicillin, teicoplanin, and vancomycin [62] . These authors concluded that the membrane-perturbing effect of CBD was not sufficient to enhance the uptake of conventional antibiotics [62] . However, Wassmann et al. [251] observed that CBD could reduce the MIC value of bacitracin against several Gram-positive bacteria, including Staphylococcus species, Listeria monocytogenes, and Enterococcus faecalis. The simultaneous use of CBD and bacitracin on MRSA USA300 resulted in the formation of multiple septa during cell division, appearance of membrane irregularities, reduced autolysis, and decreased membrane potential [251] . The combined CBD/bacitracin treatment did not affect the growth of the Gram-negative bacteria Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, and Escherichia coli [251] .

CBG was found to be active against MRSA persister cells, which are dormant, nondividing bacteria [61] . This trait is therapeutically important, since many antibiotics require cell division to be effective, and they are frequently unable to eradicate persister cells that usually recover after antibiotic withdrawal [255] [256] [257] . Another obstacle of antibiotic therapy is the development of drug resistance, a frequent reason for treatment failure [258] . Farha et al. [61] attempted to develop CBG-resistant bacteria in the hopes of finding the target molecules. Despite rechallenging the MRSA with 2x and 16x MIC concentration of CBG, they were unable to get any spontaneously CBG-resistant mutants [61] . Similarly, MRSA that had been daily exposed to sub-lethal concentration of CBD for 20 days were still sensitive to CBD [247] . The authors of these two studies [61, 247] concluded that CBD and CBG do not induce drug resistance. However, it should be noted that following exposure to CBD or CBG, the surviving growth-arrested bacteria could regain growth after withdrawal of the drug.

The hemolytic activity of CBD and CBG was found to be 256 µg/mL and 32 µg/mL, respectively, which is far above the MIC of 1-4 µg/mL for MRSA [61, 247] . Additionally, the hemolytic activity of CBDA was found to be above 32 µg/mL [62] . This makes phytocannabinoids potential drugs that can act within a reasonable therapeutic window.

Farha et al. [61] observed that treating MRSA-infected mice with a high dose of 100 mg/kg CBG could reduce the bacterial burden in the spleen by a 2.8 log 10 of CFU. Blaskovich et al. [247] tried various CBD-containing ointment formulations that could reduce a 2-3 log 10 of CFU of MRSA inoculated on porcine skin after 1 h and a reduction of more than 5 log 10 of CFU after a 24 h incubation. CBD, however, failed to significantly reduce the bacterial load of MRSA ATCC 43300 in a thigh infection mouse model [247] .

Biofilms are communities of bacteria embedded in an extracellular matrix that have attached to a biotic surface (e.g., lung tissue, gastrointestinal tract, nasal mucosa, inner ear) or an abiotic surface (e.g., medical devices, such as catheters, heart valves, stents, prostheses) [259] . The majority of infectious diseases involve bacterial biofilms that are usually difficult to eradicate due to reduced antibiotic sensitivity [259, 260] . Several studies show that CBD and CBG can prevent biofilm formation of various Gram-positive bacteria (e.g., MSSA, MRSA, Streptococcus mutans) [61, 243, 247] . The extent of anti-biofilm activity of CBD and CBG against these bacteria correlated with their anti-bacterial activity [61, 243, 244, 247] . In most cases, a similar concentration of these compounds was required to achieve both effects, suggesting that some of the anti-biofilm effect is caused by the anti-bacterial activity [61, 243, 244] . Moreover, CBD was found to be able to eradicate preformed MSSA and MRSA biofilms with a minimum biofilm eradication concentration (MBEC) of 1-4 µg/mL, indicating that CBD can penetrate the biofilms and act on the biofilm-embedded bacteria [247] . Some cannabinoids (e.g., CBD, CBG, CBC, and CBN) were shown to reduce the bacterial content of dental plaques in an in vitro assay where dental plaques were spread on agar plates coated with the cannabinoids [261] . The anti-biofilm activity of the cannabinoids has significant clinical importance, since the bacteria-embedded bacteria frequently show antibiotic resistance, and some antibiotics are unable to penetrate through the extracellular matrix of the biofilms [259, 262, 263] .

3.3.7. Anti-Fungal Biofilm Activities of Phytocannabinoids CBD barely affects the viability of Candida albicans with a MIC above 50-100 µg/mL [247, 253] , but it reduces biofilm formation with a biofilm inhibitory concentration 50 (BIC 50 ) at 12.5 µg/mL and a MBIC 90 of 100 µg/mL [253] . CBD reduced the metabolic activity of preformed Candida albicans biofilms by 50-60% at 6.25 µg/mL with no further reduction at higher concentrations, even at 100 µg/mL [253] . The morphology of the Candida albicans biofilm becomes altered in the presence of CBD. While the hyphal form was predominant in control biofilms, the CBD (25 µg/mL)-treated biofilms appeared in clusters mostly in yeast and pseudohyphal forms [253] . CBD caused a dose-dependent reduction in the cell wall chitin content and the intracellular ATP level, while increasing the intracellular reactive oxygen species (ROS) levels [253] . Gene expression studies showed that after a 24 h incubation with 25 µg/mL CBD, there is a significant downregulation of: ADH5 (Alcohol dehydrogenase 5), involved in extracellular matrix production; BIG1, required for synthesis of the extracellular matrix component β-1,6-glucan; ECE1 (extent of cell elongation protein 1), involved in biofilm formation; EED1, involved in filamentous growth; CHT1 and CHT3 chitinases, involved in the remodeling of chitin in the fungal cell wall; and TRR1 (thioredoxin reductase) with anti-oxidant properties. On the other hand, a significant upregulation of YWP1 (yeast-form wall protein 1) which is expressed predominantly in the yeast form, was observed [253] . These changes in gene expression might explain, at least in part, the reduced biofilm mass of Candida albicans in the presence of CBD and the increase in oxidative stress [253] .

There are some lines of evidence for an anti-viral activity of phytocannabinoids [60, 264] . Some phytocannabinoids, especially ∆ 9 -THC and CBD, bind to the M pro protease of SARS-CoV-2, which plays a role in viral replication [60, 264] . CBGA and CBDA were found to be allosteric and orthosteric ligands for the spike protein of SARS-CoV-2 and prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein [265] . Phytocannabinoids might indirectly relieve the disease progress of COVID-19 patients through their anti-inflammatory properties [266] . However, CBD failed to alter the clinical disease development of COVID-19 when given at a daily dose of 300 mg for 14 days [267] . Additionally, caution should be taken into account due to the immunosuppressive activities of phytocannabinoids that can prevent proper anti-viral immune responses [268] . Notably, the use of Cannabis was increased in U.S. and Canada by 6-8% during the COVID-19 pandemic in comparison to the pre-pandemic period [269] , with a special increase among people with mental health [270] . Vulnerability to COVID-19 was correlated with genetic liability to Cannabis use disorder (CUD) [271] .

The ability of phytocannabinoids such as CBD and CBG, to kill MRSA, NorA-overexp ressing Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus (VRSA), vancomycinresistant enterococci (VRE) to a similar extent as the respective antibiotic-sensitive strains [58, 245, 247] , suggests that its action mechanism is not hindered by the common antibiotic-resistance mechanisms. Thus, phytocannabinoids can be used as an alternative drug or an antibiotic adjuvant for infectious diseases caused by drug-resistant Gram-positive bacteria.

There is evidence that CBD and CBG act by targeting the cytoplasmic membrane of the Gram-positive bacteria [61, 247] . Exposure of MSSA and MRSA to CBD or CBG caused a dose-dependent increase in the fluorescence of the potentiometric probe 3,3dipropylthiadicarbocyanine iodide [DiSC3 (5)], suggesting a CBG-induced membrane depolarization [61, 247] . CBD inhibited protein, DNA, RNA, and peptidoglycan synthesis in a Staphylococcus aureus strain when using concentrations close to the MIC [247] . At sub-MIC levels, CBD inhibited lipid synthesis [247] . CBG was found to inhibit the enzyme enoyl acyl carrier protein reductase (InhA) [272] , which is involved in type II fatty acid biosynthesis in Mycobacterium tuberculosis. The rapid uptake of the SYTOX green dye into Staphylococcus aureus and Bacillus subtilis by CBD at MIC, suggests that CBD causes an increase in membrane permeability [247] .

CBG prevents the growth of oral cariogenic Streptococcus mutans in a concentration and bacterial cell density manner [243] . At a MIC of 2.5 µg/mL, CBG exhibited a bacteriostatic effect on Streptococcus mutans, while at 2x MIC and 4x MIC, a bactericidal activity was observed [243] . CBG treatment was found to alter the morphology of Streptococcus mutans and cause intracellular accumulation of membrane-like structures [243] . CBG induced an immediate membrane hyperpolarization, followed by increased uptake of propidium iodide, suggesting increased membrane permeabilization [243] . At the same time, Laurdan incorporation into the membranes was reduced in a dose-dependent manner [243] , indicative of a more rigid membrane structure. The metabolic activity was decreased in a dose-dependent manner, which might contribute to the growth inhibitory effect [243] .

Kosgodage et al. [250] observed that CBD inhibits the release of membrane vesicles from the Gram-negative Escherichia coli VCS257, while having negligible effect on the membrane vesicle release from the Gram-positive Staphylococcus aureus subsp. aureus Rosenbach. Membrane vesicles participate in inter-bacterial communication by the transfer of cargo molecules and virulence factors [273] . CBD was found to enhance the anti-bacterial effect of erythromycin, rifampicin, and vancomycin against the tested Escherichia coli strain [250] .

CBG inhibited sucrose-induced biofilm formation by Streptococcus mutans with a minimum biofilm inhibitory concentration (MBIC) of 2.5 µg/mL [243] . Higher concentrations (10 µg/mL) of CBG were required to reduce the metabolic activity of preformed Streptococcus mutans biofilms [243] . CBG reduced the expression of various biofilm-related genes (e.g., gtfB, gtfC, gtfD, ftf, gbpA, gbpA, brpA, wapA) with concomitant reduction in the production of extracellular polymeric substances (EPS) [243] . The quorum sensing-related genes comE, comD, and luxS were downregulated by CBG, while no effect was observed on the gene expression of the stress-associated chaperones groEL and dnaK [243] . Moreover, CBG induced reactive oxygen species (ROS) production in Streptococcus mutans, which might be related to the reduced expression of the oxidative stress defense genes, sod and nox [243] . Thus, CBG has specific anti-biofilm activity unrelated to its membrane-acting effect. This conclusion is further supported by the study of Aqawi et al. [248] showing that CBG inhibited quorum sensing, bacterial motility, and biofilm formation of the marine Gram-negative Vibrio harveyi without affecting the planktonic growth.

Quorum sensing is an inter-bacterial communication system mediated by secreted autoinducers that interact with their respective receptors, resulting in the activation of a signal transduction cascade that alters the gene expression repertoire in a cell-density-dependent manner [274] . CBG prevented the bioluminescence induced by the master quorum sensing regulator LuxR of Vibrio harveyi at a concentration of 1 µg/mL [248] . Using a ∆luxM, ∆lusS Vibrio harveyi mutant that does not produce autoinducers AI-1 and AI-2, CBG was found to prevent the signals delivered by exogenously added autoinducers, with a more profound inhibitory effect on the AI-2-induced than on the AI-1-induced bioluminescence [248] . Further studies show that CBG prevented the expression of several quorum sensing genes in Vibrio harveyi, including luxU, luxO, qrr1-5, and luxR, which can explain the inhibitory effect of CBG on LuxR-mediated bioluminescence [248] . Altogether, these data demonstrate that CBG can interfere with bacterial quorum sensing.

The synthetic cannabinoid HU-210, which is a dimethylheptyl analog of ∆ 8 -THC ( Figure 1 ) and acts as a high-affinity CB1 and CB2 agonist [275, 276] , has been shown to inhibit quorum sensing in the Vibrio harveyi AI-1 − , AI-2 + BB152 mutant, but it had barely any effect on the wild-type bacteria or the AI-1 + , AI-2 − MM30 mutant [249] . This suggests that HU-210 specifically antagonizes the AI-2 pathway [249] . The concentration of HU-210 required to achieve the anti-quorum sensing activity was relatively high (20-200 µg/mL) [249] , which is 2-3 magnitudes higher than that of CBG [248] . HU-210 prevented biofilm formation of the AI-1 − , AI-2 + BB152 mutant with a BIC 50 of 2 µg/mL and MBIC 90 of 200 µg/mL, while no significant effect was seen on biofilm formation by the wild-type bacteria or the AI-1 + , AI-2 − MM30 mutant [249] . However, the motility of Vibrio harveyi was reduced in all three strains at both 20 and 200 µg/mL HU-210 [249] . Gene expression studies showed that HU-210 at a concentration of 2 µg/mL reduced the expression of the master regulator luxR in both wild-type and AI-1 − , AI-2 + BB152 strain, while it had no effect on the AI-1 + , AI-2 − MM30 Vibrio harveyi mutant strain [249] . The luxM gene that encodes for AI-1 was upregulated by HU-210 [249] .

The endocannabinoid system (ECS) modulates many physiological processes, including the cardiovascular, gastrointestinal and immune systems, pain, learning, memory, perception, mood, appetite, metabolism, emotions, and sleep [22, 112, 113, [277] [278] [279] [280] [281] [282] [283] [284] [285] . The bioactive endocannabinoid lipid mediators have potent anti-inflammatory activities [286] [287] [288] [289] [290] [291] . In addition, they promote neural progenitor cell proliferation and differentiation, and have neuroprotective effects [20, [292] [293] [294] . The effect on neural cell proliferation is mediated by both the CB1 and CB2 receptors [293, 295, 296] .

The endocannabinoid system is composed of: (1) the lipid active endogenous ligands N-Arachidonoylethanolamine (anandamide; AEA) and 2-arachidonoylglycerol (2-AG);

(2) their biosynthetic enzymes (e.g., diacylglycerol lipases (DAGL), N-acyl-phosphatidyletha nolamine phospholipase D-like esterase (NAPE-PLD), and Ca 2+ -dependent and Ca 2+independent N-acetyltransferases); (3) their degradative enzymes (e.g., fatty acyl amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)); and (4) the CB1 and CB2 cannabinoid receptors [15, 297, 298] . The precursors of endocannabinoids (e.g., N-acylphosphatidylethanolamine (NAPE) and phosphatidylinositol-4,5-bisphosphate (PIP2)) are present in the lipid membranes, and the endocannabinoids are produced upon demand, usually after activation of certain G-protein-coupled receptors (GPCRs) and in response to an increase in the intracellular calcium levels [299] [300] [301] [302] .

The production of endocannabinoids requires one or two enzymatic steps, followed by their release into the extracellular space. AEA is usually produced from N-arachidonoylphosphatidylethanolamine phospholipid, and 2-AG is produced primarily from membrane phospholipid 1-stearoyl-2-arachidonoyl-sn-glycerol [297] . The synthesis of 2-AG involves two steps: first, the hydrolysis of its precursor phospholipid by a phospholipase (PLCβ, PLCγ2, or PLCε), followed by further cleavage by diacylglycerol lipase (DAGL) [303] [304] [305] .

The biosynthesis of these endocannabinoids occurs in areas of the brain functionally related to cognitive processes, motivation, and movement control [306, 307] . 2-AG was found to be present at 170 times higher concentrations than AEA in brain lysate [308] . While AEA was initially detected in the brain [135] and 2-AG in the canine gut [309] , today it is known that these host-derived endocannabinoid lipid hormones are found in various peripheral tissues (e.g., the intestine) and in the serum, and produced by certain immune cells [23, 290, [309] [310] [311] [312] [313] [314] [315] [316] [317] . For instance, lipopolysaccharides induced the production of AEA in adipose tissue macrophages [318] . T and B cells produce elevated levels of 2-AG upon activation [290] . Astrocytes were found to produce AEA, as well as homo-γlinolenoylethanolamine (HEA), docosatetraenoylethanolamine (DEA), oleoylethanolamine (OAE), and palmitoylethanolamine (PEA) [319] .

The circulating endocannabinoid levels are affected by various factors, and under physiological conditions, the AEA serum level was found to be between 1 to 5 nM, and the 2-AG serum level between 10-500 nM [316, 320] . Physical exercise mobilizes endocannabinoids, which could contribute to the analgesic and mood-elevating effects of exercise [316] . The circulating levels of 2-AG show a circadian rhythm that gets altered when sleep is disrupted [316, 320] . CBD inhibits the degradation of AEA and 2-AG, which is associated with the anti-inflammatory and anti-oxidative activities [321] .

AEA and 2-AG act as agonists of the CB1 and CB2 receptors [135, [322] [323] [324] [325] . While 2-AG binds with high affinity to CB1 and CB2 cannabinoid receptors, AEA binds with low affinity to these receptors [323, 324] . Although phytocannabinoids and endocannabinoids bind to the same CB1 and CB2 receptors, their chemical structure is quite different [297] (Figures 1 and 3) . Both AEA and 2-AG have an alkyl-amide (alkamide) chemical structure, while cannabinoids are terpenophenolic compounds.

In addition to acting on CB1 and CB2, AEA activates the ionotropic TRPV1 channel, resulting in the opening of the ion channel and Ca 2+ influx [312, [326] [327] [328] [329] [330] [331] , the Gprotein-coupled receptor GPR55 [332, 333] , and the cation channel TRPA1 [334] , while it inhibits the TRPM8 channel [334] . In addition, AEA activates PPARγ, and 2-AG activates PPARα [335] . The vasodilation action of AEA was found to be mediated via activation of TRPV1 [336] . Endocannabinoids activating TRPV1 have been included in the endovanilloid system [337] [338] [339] . Recent studies suggest that potassium channels are also the targets of endocannabinoids [340] .

In the brain, endocannabinoids serve as retrograde synaptic messengers [299, 341] . They are released from postsynaptic neurons and inhibit the release of presynaptic neurotransmitters, such as glutamate and gamma-aminobutyric acid (GABA) by binding to the CB1 receptor and TRPV1 expressed in the presynaptic terminals [299, 342, 343] . This has led to the hypothesis that endocannabinoids regulate over-excitability and promote synaptic homeostasis [344] . Endocannabinoids differ from the classical neurotransmitters in that they are not stored in vesicles but are released immediately after their production.

The solubility of endocannabinoids is low in water, raising the question of how AEA diffuses through the synaptic cleft [345] . There is evidence that AEA can interact with cholesterol and ceramide, which are required for their insertion into and transport through the membrane [345] [346] [347] . In the brain, the lipid-binding protein α-synuclein is involved in the transport of arachidonic acid [348] . Fatty acid binding proteins have been shown to be intracellular carriers of AEA [349] . Another communication system that exists between neurons is the release of lipidbased transport systems such as exosomes from neurons following a synaptic response, that are taken up by neighboring cells [350, 351] . Gabrielli et al. [352] observed that endocannabinoids are secreted on extracellular membrane vesicles. In this study, extracellular vesicles secreted by microglial cells were found to carry AEA on their surface that was able to stimulate the CB1 receptor expressed on neurons and inhibit presynaptic transmission [352] . Microglial cells release endocannabinoids at much higher levels than neurons and astrocytes [319, 353, 354] and are thought to play a role in regulating the synaptic activity by a process termed gliotransmission, which functions to bridge the non-synaptic inter-neuronal communication [355] .

Other endocannabinoids include the oleoyl-and palmitoyl-ethanolamines (OEA and PEA) that affect intestinal permeability by acting on TRPV-1 and PPARα [356, 357] , and 2-AG-ether and O-arachidonoylethanolamine (virodhamine) [22, 358] (Figure 3 ). PEA is produced by neurons, microglia, and astrocytes in the central nervous system [359, 360] where it plays an important role in neuroprotection [361, 362] . Moreover, it was shown to have both anti-nociceptive and anti-inflammatory activities [363] [364] [365] [366] . Immune cells release PEA that activates the CB2 receptor, resulting in downregulation of the inflammatory processes [367, 368] . PEA, which is synthesized along with AEA, potentiates the action of AEA by increasing receptor affinity or reducing the degradation of AEA by FAAH [357, [369] [370] [371] . The study of Lo Verme et al. [372] showed that PPARα was required for the anti-inflammatory effect of PEA. Borrelli et al. [365] observed that PEA alleviates the inflammation in a murine colitis model through acting on CB2, GPR55, and PPARα. OEA acts on PPARα and is secreted in the proximal intestine where it controls appetite, exhibits anti-inflammatory properties, and stimulates lipolysis and fatty acid oxidation [373] [374] [375] [376] .

The endocannabinoid noladin ether acts on CB2 and inhibits the intracellular effector adenylyl cyclase [377] . The endocannabinoid virodhamine, which is composed of arachidonic acid and ethanolamine joined by an ester linkage, is a partial agonist with an antagonist activity on CB1, while being a full agonist on CB2 [378] . At low concentrations, virodhamine activates GPR55, while at high concentrations it acts as an antagonist [379] . The endocannabinoid N-arachidonoyl-dopamine (NADA), which is highly expressed in the striatum, hippocampus, and cerebellum, activates TRPV1, induces the release of substance P and calcitonin gene-related peptide from dorsal spinal cord slices, and enhances hippocampal paired-pulse depression [380] . NADA and its epoxide metabolites also act as an agonist for the CB1 and CB2 receptors and show anti-inflammatory activities [337, [381] [382] [383] . Other dopamine-related endocannabinoids include N-oleoyldopamine (OLDA), N-palmitoyldopamine (PALDA), and N-stearoyldopamine (STEARDA) [384] . OLDA is only a weak ligand of CB1, but it induced calcium influx, reduced the latency of paw withdrawal from a radiant heat source, and produced nocifensive behavior [384] .

N-Arachidonoyl-L-serine (AraS) is an endogenous bioactive lipid found both in the central nervous system (CNS) and in the periphery, with a similar structure and physiological functions as AEA [385, 386] (Figure 3 ). It possesses vasoactive, pro-angiogenic, pro-neurogenic, and neuroprotective properties [386] [387] [388] . Since AraS binds weakly to CB1 and CB2, it is not classified as an endocannabinoid, but rather has been coined as an "endocannabinoid-like" substance [386] . The pro-angiogenic activity of AraS is achieved by activation of GPR55 [387] . Moreover, AraS stimulates phosphorylation of MAPK and Akt protein kinases [385] .

The anti-microbial effect of endocannabinoids depends on the strain studied and the endocannabinoid used [16] [17] [18] 389, 390] (Table 2) . Among the tested organisms, Streptococcus salivarius, Bacteroides fragilis, and Enterococcus faecalis were the most susceptible bacteria to AEA and N-Linoleoylethanolamine (LEA) [390] . MSSA and MDRSA become immediately growth arrested by AEA, an effect that was transient and relieved upon time [16] . On the other hand, the growth of Lactobacillus gasseri species becomes enhanced by LEA and OEA [390] . It had no effect on the growth of Ruminococcus gnavus ATCC 29149 at 100 µM, with a small delay in the log-phase growth at 200 µM.

It had no effect on the growth of Escherichia coli AIEC NC101, even at 200 µM.

[390] [18] . A kinetic study of AEA on a multidrug-resistant Staphylococcus aureus (MDRSA) clinical isolate and the MSSA ATCC 25923 strain showed that AEA caused a transient bacteriostatic effect that was overcome with time [16] . The bacteriostatic effect of AEA was independent of the drug-resistant phenotype [16] . Further analysis showed that AEA inhibited cell division just prior to daughter cell separation [16] . Gene expression studies showed that AEA reduced the expression of some autolysin genes, which might in part contribute to the growth arrest [16] . AEA altered the membrane structure of the MDRSA and caused an immediate membrane depolarization that recovered with time [16] . Both AEA and AraS reduced the hydrophobicity index of MRSA at a concentration of 16 µg/mL [18] .

Importantly, it was observed that AEA and AraS sensitize MRSA and MDRSA strains to various antibiotics, including β-lactam antibiotics (ampicillin and methicillin), gentamicin, tetracycline, and norfloxacin [16, 17] . For instance, the MIC of ampicillin against MRSA ATCC 33592 and ATCC 43300 was 128 and 256 µg/mL, respectively, but in the presence of 8-16 µg/mL AEA, it was reduced to 8 µg/mL [17] . The MIC of gentamicin against MRSA ATCC 33592 was 128 µg/mL, but in the presence of 8 µg/mL AEA, it was reduced to 4 µg/mL [17] . Treating a MDRSA clinical isolate with 50 µg/mL AEA reduced the MIC of methicillin from above 500 µg/mL to 50 µg/mL [16] . AEA was found to prevent drug efflux, resulting in intracellular drug accumulation, which might explain, at least in part, the sensitization of the bacteria to antibiotics [16] . Gene expression analysis shows that AEA reduces the expression of some efflux pump genes, including norB, norC, mepA, kdpA, and opp1C in MDRSA [16] , but it is likely that the alterations in the membrane structure caused by AEA also contribute to intracellular drug retention.

It is notable that the sensitization of MRSA to methicillin takes place even when bacterial growth is inhibited by AEA [16] , suggesting that the anti-bacterial effect of methicillin and other β-lactams does not require cell division as previously documented when used as a single agent [391, 392] . Indeed, FtsZ inhibitors that arrest bacterial cell growth, also sensitize drug-resistant Staphylococcus aureus to β-lactam antibiotics, which was related to membrane relocalization of penicillin-binding proteins (PBPs) [393] . Further studies are required to fully understand the antibiotic-sensitization mechanisms of AEA and AraS. 4.6.3. AEA and AraS Exhibit Anti-Biofilm Activity against Drug-Sensitive and Drug-Resistant Staphylococcus aureus AEA and AraS prevent biofilm formation of MRSA and MDRSA with a maximum effect at 12.5-35 µg/mL [16, 18] . AEA and AraS had a rather weak effect on preformed biofilm of MRSA and MDRSA, where concentrations as high as 64 µg/mL were required to eradicate 50% of the biofilms after a 24 h incubation [16, 18] . The simultaneous treatment of the MRSA and MDRSA strains with endocannabinoids and antibiotics significantly lowered the effective dose of the two compounds [16, 17] . For instance, the MBICs of AEA and ampicillin on MRSA ATCC 33592 were, respectively, 33.8 and 128 µg/mL, while in combination, 8 µg/mL of each compound was required for inhibiting biofilm formation [17] . When combining the sub-MBIC concentration 3.125 µg/mL of AEA with 50 µg/mL norfloxacin, which, as a single agent, had no anti-biofilm effect, an 80% reduction in biofilm formation by MDRSA was observed [16] . A 90% reduction in preformed MDRSA biofilm was observed when 50 µg/mL of AEA was combined with 50 µg/mL methicillin, which is the synergistic condition required for killing the bacteria [16] . The latter observation shows that the combination of AEA with antibiotics is also effective against biofilm-embedded bacteria.

Gene expression studies showed that AEA reduced the expression of the regulatory RNAIII and the virulence gene α-helical phenol-soluble modulin (psmα) in MDRSA [16] . Additionally, the genes fnbB, hla, and hld encoding for the virulence factors fibronectin binding protein, α-hemolysin and δ-hemolysin (δ-toxin), respectively, were downregulated by AEA [16] . As Psmα plays a central role in Staphylococcus aureus biofilm formation by stabilizing the biofilms through amyloid formation [394] [395] [396] , the inhibition of its expression might be one mechanism for the anti-biofilm effect of AEA (Figure 4 ). transition, but this concentration was sufficient to prevent hyphal extension [389] . Importantly, Candida albicans hyphae that have been exposed to AEA at 50 μg/mL and higher concentrations showed strong reduction in their ability to adhere to the HeLa cervical epithelial carcinoma cells [389] . AraS-treated Candida albicans hyphae showed deficient adherence to HeLa cervical carcinoma cells similar to AEA-treated fungi, while 2-AG treatment had only a minor effect at the concentrations analyzed (up to 250 μg/mL) [389] . None of the endocannabinoids affected the adherence of the Candida albicans hyphae to polystyrene tissue culture plates within the first hour of incubation, while AraS and 2-AG, but not AEA, reduced the biofilm mass formed on the polystyrene tissue culture plates after a 24 h incubation [389] .

Gene expression studies showed that AEA increased the expression of NRG1, which is a transcriptional repressor of filamentous growth, but reduced the expression of the hyphal cell wall protein 1 (HWP1), the Agglutinin-like protein 3 (ALS3), the Hypha-specific G1 cyclin-related protein 1 (HGC1), the Ras-like protein 1 (RAS1), the enhanced filamentous growth protein 1 (EFG1), the cell surface hydrophobicity-associated protein CSH1, and the extent of cell elongation protein 1 (ECE1). The combined effect of AEA on the expression of these genes might cumulate in the observed effects of AEA on Candida albicans adherence and hyphal growth ( Figure 5 ). 

Adhesion of Candida albicans Hyphae to Epithelial Cells AEA and AraS were found to inhibit yeast-hypha transition of Candida albicans at 125 and 250 µg/mL [389] . At 50 µg/mL, there was only a partial inhibition on the yeasthypha transition, but this concentration was sufficient to prevent hyphal extension [389] . Importantly, Candida albicans hyphae that have been exposed to AEA at 50 µg/mL and higher concentrations showed strong reduction in their ability to adhere to the HeLa cervical epithelial carcinoma cells [389] . AraS-treated Candida albicans hyphae showed deficient adherence to HeLa cervical carcinoma cells similar to AEA-treated fungi, while 2-AG treatment had only a minor effect at the concentrations analyzed (up to 250 µg/mL) [389] . None of the endocannabinoids affected the adherence of the Candida albicans hyphae to polystyrene tissue culture plates within the first hour of incubation, while AraS and 2-AG, but not AEA, reduced the biofilm mass formed on the polystyrene tissue culture plates after a 24 h incubation [389] .

Gene expression studies showed that AEA increased the expression of NRG1, which is a transcriptional repressor of filamentous growth, but reduced the expression of the hyphal cell wall protein 1 (HWP1), the Agglutinin-like protein 3 (ALS3), the Hypha-specific G1 cyclin-related protein 1 (HGC1), the Ras-like protein 1 (RAS1), the enhanced filamentous growth protein 1 (EFG1), the cell surface hydrophobicity-associated protein CSH1, and the extent of cell elongation protein 1 (ECE1). The combined effect of AEA on the expression of these genes might cumulate in the observed effects of AEA on Candida albicans adherence and hyphal growth ( Figure 5 ). 

An intercommunication system has been found to exist between the gut microbiota and the endocannabinoid system [285, 298, [397] [398] [399] [400] [401] [402] . The gut microbiota, representing more than 100 trillion microorganisms, including at least 1000 distinct species, lives in symbiosis with the host and assists in controlling the metabolic health of the host by degrading nutrients that the host is unable to digest and by providing a whole battery of small signaling molecules, metabolites, and nutrients beneficial for the host physiology [298, 403] . The gut microbiome differs from individual to individual, and the composition Figure 5 . Effect of AEA on Candida albicans gene expression [381] . Genes in red are downregulated by AEA after a 2 h incubation. Genes in green are upregulated by AEA. Genes in light blue are unaffected by AEA. Open circles are genes that have not yet been analyzed. Ultimately, AEA prevents the adherence and hyphal extension of Candida albicans.

An intercommunication system has been found to exist between the gut microbiota and the endocannabinoid system [285, 298, [397] [398] [399] [400] [401] [402] . The gut microbiota, representing more than 100 trillion microorganisms, including at least 1000 distinct species, lives in symbiosis with the host and assists in controlling the metabolic health of the host by degrading nutrients that the host is unable to digest and by providing a whole battery of small signaling molecules, metabolites, and nutrients beneficial for the host physiology [298, 403] . The gut microbiome differs from individual to individual, and the composition of the microbiota is believed to affect various metabolic disorders, such as obesity, hyperglycemia, and dyslipidemia, which are risk factors for type 2 diabetes, hepatosteatosis, and arteriosclerosis [404] . Reduced diversity of gut microbiota has been linked with various pathophysiological conditions, such as depression, schizophrenia, neurological disorders, and chronic fatigue [405] [406] [407] [408] [409] . Microbiota can affect the endocannabinoid system and the nervous system, and vice versa; the nervous system and the endocannabinoids can influence the enteric microbiota composition [112, 285, 390, 397, 410, 411] .

The effect of the gut microbiota on depressive-like behaviors in mice was found to be mediated by the endocannabinoid system [411] . These authors showed that the transfer of microbiota from stress-induced depressive mice to naïve unstressed hosts induced a depressive-like state in the recipients. This was accompanied by a reduced adult hippocampal neurogenesis that was related to decreased hippocampal 2-AG levels and deficient CB1-mediated activation of the mTOR signaling pathways [411] . The detrimental effects on hippocampal neurogenesis could be restored by a MAGL inhibitor that prevents 2-AG degradation, addition of the 2-AG precursor arachidonic acid to the diet, or by complementation with Lactobacillus plantarum WJL [411] . The microbiota from the stressinduced depressive mice showed an increase in Ruminococcaceae and Porphyromonodaceae species, with a decrease in Lactobacillaceae [411] . The complementation with Lactobacillus plantarum WJL restored hippocampal 2-AG to normal levels, as well as increased the levels of AEA, n-3, and n-6 polyunsaturated fatty acids (PUFAs) [411] . Lactobacillus species can regulate fatty acid metabolism, absorption, and fatty acid composition of the host [412, 413] , which in turn affects the endocannabinoid system [411] . Rousseaux et al. [414] observed that oral administration of Lactobacillus acidophilus induced the expression of both the µ 1 opioid receptor and CB2 receptor on colon epithelial cells, resulting in reduced abdominal pain in a rat colorectal distension model.

PEA was shown to mediate the association between gut microbial diversity and anhedonia/amotivation [410] . Increased serum levels of PEA were associated with antidepressive effects [357, 415] , while increased stool levels of PEA, indicative of increased excretion of PEA, were associated with alterations in synaptic plasticity, learning, and emotional responses [410, 416, 417] . The stool PEA levels were associated with gut microbial diversity, with implications on host mental health [285, 357, 410, 418] . The relative abundance of microbes of the Blautia and Dorea taxa was particularly associated with fecal PEA and anhedonia/amotivation [410] . Reduced microbial diversity corresponded with increased excretion of PEA and more severe anhedonia/amotivation [410] . PEA was also found to counteract autistic-like behaviors in BTBR T + tf /J mice by dampening inflammation, reducing oxidative stress, reducing gut permeability, and altering the gut microbiota, besides its neuroprotection through induction of PPARα [419] . These authors found that PEA treatment increased the ratio of Firmicutes/Bacteroidetes, which was due to an increase in Firmicutes (e.g., Clostridials) and a decrease in Bacteroidetes [419] . 4.7.3 . The Relationship between Gut Microbiota, AEA, and Acute Respiratory Distress Syndrome AEA was found to attenuate acute respiratory distress syndrome through modulating the gut microbiota [420] . In this study, the researchers investigated the effect of AEA on staphylococcal enterotoxin B (SEB)-mediated acute respiratory distress syndrome. SEB caused an increase in pathogenic bacteria in both the lungs and the gut [420] . AEAtreated mice showed increased level of anti-microbial peptides in the lung epithelial cells and prevented the increase in pathogenic bacteria induced by SEB [420] . AEA increased the level of several bacterial species (e.g., Lachnospiraceae and Clostridia) that produce elevated levels of SCFAs, such as butyrate and valerate, important for stabilizing the gut-lung microbial axis and suppressing inflammation [420] . In addition, AEA treatment increased the abundance of Muribaculaceae and reduced the abundance of Pseudomonas and Enterobacteriaceae [420] .

Obesity is often characterized by low-grade inflammation, with increased levels of endocannabinoids in the plasma and adipose tissues and altered expression of CB1 [421] . Activation of CB1 and CB2 receptors reduces motility, limits secretion, and decreases hypersensitivity in the gut [422] [423] [424] . Impaired CB1 signaling protected against the development of obesity and steatosis [425] [426] [427] . Lipopolysaccharides from Gram-negative bacteria induce the production of endocannabinoids under inflammatory conditions that dampen the inflammatory response [318, [428] [429] [430] . Vice versa, the activation of CB1 in mice increases circulating levels of lipopolysaccharides due to reduced expression of the tight junction proteins occludin and zonula occludens-1 (ZO-1), resulting in increased gut epithelial permeability [421, 431] .

The gut microbiota was found to modulate colon CB1 receptor expression in both normal and obese mice [421] . Obese mice fed with the prebiotic oligofructose showed reduced CB1 expression, lower AEA content, and increased expression of FAAH [421] . Obese mice treated with the CB1 antagonist SR141716A (Rimonabant) improved the gut barrier function and reduced body weight gain [421] . Mehrpouya-Bahrami et al. [432] observed that SR141716A attenuated diet-induced obesity and inflammation that was correlated with increased relative abundance of Akkermansia muciniphila and decreased abundance of Lanchnospiraceae and Erysipelotrichaceae in the gut. Interestingly, SR141716A prevented the intracellular replication of macrophage-phagocytosed Brucella suis by activating the macrophages, which was related to the inhibition of CB1 [433] . It would be interesting to study whether SR141716A also has a direct anti-microbial effect. In this context, it is worth mentioning that SR141716A could potentiate the anti-fungal activity of amphotericin B against Candida albicans and Cryptococcus neoformans by increasing cellular oxidative stress and cell membrane permeability [434] .

Mice fed on high-fat, high-glucose diet showed altered microbiome with concomitant increase in AEA and 2-AG in the plasma [398] . The relative abundances of Adlercreutzia, Barnesiella, Coprobacillus, Eubacterium, and Parasutterella in the ileum were negatively associated with AEA levels [398] . The level of the AEA congener N-docosahexaenoylethanolamine (synaptamide, DHEA), which is required for normal brain development [435] , was negatively associated with Barnesiella, Enterococcus, Eubacterium, Flavonifractor, and Intestinimonas in the ileum [398] . These authors also found a negative correlation between the Delftia genus and N-linoleoylethanolamine (LEA), while the Lactobacillus genus was associated with increased 2-docosahexaenoyl-glycerol (2-DHG) levels [398] .

Repeated administration of OAE to mice fed on normal chow pellet diet for 11 days led to alteration in fecal microbial composition with an increase in Bacteroidetes (e.g., Bacteroides genus) and a decrease in Firmicutes (Lactobacillus), which is considered a "lean-like" phenotype [436] . OAE also reduced intestinal cytokines expression by immune cells isolated from Peyer's patches [436] .

Both AEA and PEA have been observed to reduce inflammation in murine models of colitis and inflammatory bowel disease [437] [438] [439] . Elevating the levels of the endocannabinoids by inhibiting FAAH could relieve colitis and inflammatory bowel disease [440, 441] . Butyrate that is produced by gut microbiota (e.g., bacteria of the Ruminococcaceae and Lachnospiraceae family) [442] reduces inflammation and pain in colitis animal models, which can in part be mediated through the endocannabinoid system [443] . Vijay et al. [443] studied the association of the endocannabinoids AEA, 2-AG, OEA, and PEA with gut microbiome composition upon exercise. Under resting condition, AEA and OEA were positively associated with alpha diversity and with SCFA producing bacteria such as Bifidobacterium, Coprococcus 3, and Faecalibacterium, while being negatively associated with Collinsella [443] . AEA, OEA, and PEA increased with exercise, and changes in AEA correlated with bacterial butyrate production [443] . The increases in AEA and PEA correlated with decreased expression of the inflammatory mediators TNFα and IL-6 and increased expression of the anti-inflammatory cytokine IL-10 [443] .

PEA was found to increase the phagocytosis and intracellular killing of encapsulated Escherichia coli K1 by activated microglial cells and macrophages [444, 445] . Pre-treatment with PEA significantly increased the survival of mice challenged with Escherichia coli K1 [445] . Similarly, Heide et al. [446] observed that prophylactic PEA attenuated inflammation and increased the survival of mice challenged with intracerebral Escherichia coli K1 infection. Lower bacterial loads were observed in the spleen, liver, and blood of the PEA pretreated animals [446] . This was related to the anti-inflammatory effect, since PEA at 1 µg/mL had no effect on Escherichia coli growth in vitro [446] .

The gut microbiota of IBD patients differs from healthy individuals, with a decrease in butyrate-and indole-producing bacteria, decrease in bile salt-sensitive bacteria, while an enrichment in bile acid-metabolizing bacteria [390, [447] [448] [449] . Among others, Escherichia coli, Lactobacillus gasseri, Ruminococcus gnavus, and Blautia producta, were more abundant in IBD, while Bacteroides cellulosilyticus, Bacteroides fragilis, and Streptococcus salivarius were depleted [390] . Fornelos et al. [390] observed that certain N-Acylethanolamines (NAEs), such as LEA, PEA, OEA and AEA, are elevated in the stool of IBD, Crohn's disease, and/or ulcerative colitis patients, and stimulate the growth of bacterial species overrepresented in IBD while inhibiting bacterial species lacking in IBD. N-acylethanolamine levels were highest in samples with most differences in the microbiome, suggesting a connection between N-Acylethanolamines and altered microbiota in IBD [390] . These researchers observed that LEA inhibited the growth of Bacteroides fragilis, Bacteroides cellulosilyticus, and Enterococcus faecalis, while slightly enhanced the growth of Escherichia coli, Ruminococcus gnavus, and Blautia producta [390] . AEA also transiently inhibited the growth of Bacteroides fragilis and Enterococcus faecalis that recovered with time [390] . The growth of Lactobacillus gasseri, which is enriched in IBD, was enhanced by OEA and LEA, and to a lesser extent by AEA [390] . LEA and AEA partly inhibited the growth of Alistipes shahii and Ruminococcus lactaris that are underrepresented in IBD subjects [390] . The growth of Streptococcus salivarius was completely prevented at a concentration of 50 µM LEA, AEA, or OEA, but only slightly inhibited by PEA [390] .

Fornelos et al. [390] also studied the effect of N-acylethanolamines, including endocannabinoids, on the composition of two different stool chemostats. In the control chemostat A, the Enterobacteriaceae, Clostridiaceae, and Veillonellaceae taxa dominated, while in the presence of AEA, the bacterial community was almost entirely overtaken by Enterobacteriaceae [390] . LEA-treated chemostat A was dominated by Enterococcaceae, Veillonellaceae and Enterobacteriaceae at the expense of Streptococcaceae, Erysipelotrichaceae, Porphyromonadacea, Bacteroidaceae, and Rikenellaceae, while OEA treatment did not impact Enterobacteriaceae abundance but increased the relative abundances of Enterococcaceae and Streptococcaceae and decreased those of Bacteroidaceae and Rikenellaceae [390] . AEA and LEA also reduced the abundance of Barnesiella intestinihominis, Alistipes, and Bacteroides species, while they increased the abundance of Escherichia species [390] . In Chemostat B, the abundance of Blautia producta, Clostridium clostridioforme, Klebsiella pneumoniae, and Proteus mirabilis was increased in the presence of AEA or LEA [390] . These data indicate that LEA, AEA, and other N-Acylethanolamines can shift the microbiome of a healthy individual into an IBD profile [390] .

Transcriptional analysis showed that AEA upregulates both the anaerobic, reductive, and oxidative branches of the citrate cycle concomitant with increased energy metabolism and increased respiratory electron transport chain activity, especially in Enterobacteriaceae [390] . Metabolic changes occurring upon exposure to AEA, LEA, and other NAEs include the activation of bacterial processes involved in NAE metabolism [390] .

Searching for an action mechanism of LEA and AEA on Bacteroides fragilis, the researchers found that the most upregulated genes are those encoding for membraneassociated efflux transport proteins, and the most downregulated gene was the long chain fatty acid (LCFA) importer fadL [390] . They further showed that two other genes involved in fatty acid metabolic processing were repressed: a fadD homolog that catalyzes esterification of incoming fatty acids into CoA thioesters and a fadE homolog involved in downstream fatty acid breakdown [390] . These data indicate that bacteria have developed mechanisms that can respond to endocannabinoids.

Both phytocannabinoids and endocannabinoids have diverse physiological activities that are, in part, mediated by common receptors in mammalians, each compound with its specificity and affinity, being agonists, partly agonists, inverse agonists, or antagonists. While these mechanisms have been widely investigated, the mechanisms leading to their anti-microbial effects are less understood. Despite the quite different structures of phytocannabinoids and endocannabinoids (Figures 1 and 3) , there are some common dominators that characterize their anti-bacterial activities (Figures 2 and 4) . For instance, they exert bacteriostatic activity, alter the membrane structure, induce either membrane hyperpolarization or depolarization, modulate gene expression including those involved in metabolism, affect virulence factors, and prevent biofilm formation (Figures 2 and 4) . Additionally, the AEA-mediated inhibition of yeast-hypha transition of Candida albicans and the hyphal adherence to epithelial cells seem to be mediated by alterations in gene expression ( Figure 5 ). The multiple actions of phytocannabinoids and endocannabinoids suggest that the compounds do much more than just affecting membrane permeability as previously thought.

The emergence of antibiotic-resistant microbes is a clinical problem worldwide, and novel treatment strategies are urged. The important observation that some of the phytocannabinoids and endocannabinoids act on both drug-sensitive and drug-resistant Staphylococcus aureus makes them potential antibiotic adjuvants in treating drug-resistant infections, for instance for topical infectious wound treatment. Especially important is the ability of AEA and AraS to sensitize drug-resistant Staphylococcus aureus to antibiotics in virtue of their ability to prevent drug efflux and induce growth arrest. The addition of these endocannabinoids to the treatment cocktail will revive the use of already existing antibiotics. The ability of both CBG and the synthetic cannabinoid HU-210 to antagonize quorum sensing may have implications in the new era where quorum sensing inhibitors or quorum quenchers have attracted attention for alternative antibiotic drugs for antibioticresistant bacteria [450] . To reach this goal, further studies should be performed to clarify the spectrum of bacteria whose quorum sensing pathways are affected by cannabinoids. The increasing recognition of the complex interplay between the gut microbiota and the endocannabinoid system with the accompanying implications for various physiological and pathophysiological conditions, places the therapeutic uses of cannabinoids into a new spotlight. 

The role and place of medicinal plants in the strategies for disease prevention

Medicinal Plants of the World, Volumes 3: Chemical Constituents, Traditional and Modern Medicinal Uses

Plant secondary metabolites in the battle of drugs and drug-resistant bacteria: New heroes or worse clones of antibiotics?

Antimicrobial plant metabolites: Structural diversity and mechanism of action

Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives

Elucidating the effect of anti-biofilm activity of bioactive compounds extracted from plants

The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety

Chapter 2: Plants secondary metabolites: The key drivers of the pharmacological actions of medicinal plants

Barros de Oliveira, D. Plants as sources of anti-inflammatory agents

New perspectives on the use of phytochemicals as an emergent strategy to control bacterial infections including biofilms

Role of cannabinoids in various diseases: A review

Cannabinoids in health and disease

Therapeutic prospects of cannabinoids in the immunomodulation of prevalent autoimmune diseases

Early phytocannabinoid chemistry to endocannabinoids and beyond

Anandamide alters the membrane properties, halts the cell division and prevents drug efflux in multidrug resistant Staphylococcus aureus

Potential combinations of endocannabinoid/endocannabinoid-like compounds and antibiotics against methicillin-resistant Staphylococcus aureus

Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus

Comparative evaluation of combinatory interaction between endocannabinoid system compounds and Poly-L-lysine against Streptococcus mutans growth and biofilm formation

The endocannabinoid system in normal and pathological brain ageing

Turning Over a New Leaf: Cannabinoid and endocannabinoid modulation of immune function

Endocannabinoid signalling in innate and adaptive immunity

Endocannabinoid signaling at the periphery: 50 years after THC

The origin and use of Cannabis in eastern Asia linguistic-cultural implications

Medical Cannabis: A plurimillennial history of an evergreen

A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs

The religious and medicinal uses of Cannabis in China, India and Tibet

Antibacterial cannabinoids from Cannabis sativa: A structure-activity study

The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids

Antimicrobial and antiviral (SARS-CoV-2) potential of cannabinoids and Cannabis sativa: A comprehensive review

Uncovering the hidden antibiotic potential of Cannabis

Isolation, purification, and antimicrobial characterization of cannabidiolic acid and cannabidiol from Cannabis sativa L

Biologically active cannabinoids from high-potency Cannabis sativa

Antibacterial substances in seeds

Antimicrobial studies of the leaf of Cannabis sativa L

Antimicrobial activity of Cannabis sativa L

Essential oils of different cultivars of Cannabis sativa L. and their antimicrobial activity

Chromatographic analyses, In vitro biological activities, and cytotoxicity of Cannabis sativa L. essential oil: A multidisciplinary study

In vitro antioxidant and antimicrobial activity of Cannabis sativa L. cv 'Futura 75' essential oil

The crop-residue of fiber hemp cv. Futura 75: From a waste product to a source of botanical insecticides

Insecticidal properties of essential oil of Cannabis sativa Linn. against mosquito larvae

Effect of the distillation time on the chemical composition, antioxidant potential and antimicrobial activity of essential oils from different Cannabis sativa L. cultivars

How different are their essential oil profile and antimicrobial activity? Molecules

Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

The antimicrobial effect behind Cannabis sativa

The antimicrobial activity of cannabinoids

Biological activities of Korean Citrus obovoides and Citrus natsudaidai essential oils against acne-inducing bacteria

Biological activities of α-pinene and β-pinene enantiomers

Inhibitory effect of β-pinene, α-pinene and eugenol on the growth of potential infectious endocarditis causing Gram-positive bacteria. Rev. Bras. De Ciências Farm

The antibacterial effects of myrcene on Staphylococcus aureus and its role in the essential oil of the tea tree (Melaleuca alternifolia)

Terpenoids inhibit Candida albicans growth by affecting membrane integrity and arrest of cell cycle

Antimicrobial susceptibility and antibacterial mechanism of limonene against Listeria monocytogenes

Limonene inhibits streptococcal biofilm formation by targeting surfaceassociated virulence factors

Antifungal activity of the volatiles of high potency Cannabis sativa L. against Cryptococcus neoformans

Antileishmanial activity of the terpene nerolidol

Antimalarial use of volatile oil from leaves of Virola surinamensis (Rol.) Warb. by Waiãpi Amazon Indians

Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum

The anticancer, antioxidant and antimicrobial properties of the sesquiterpene β-caryophyllene from the essential oil of Aquilaria crassna

Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis

Phytochemistry of Cannabis sativa L

Methods for quantification of cannabinoids: A narrative review

Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR

Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor

Determination of acid and neutral cannabinoids in extracts of different strains of Cannabis sativa using GC-FID

Cannabis Pharmacology: The usual suspects and a few promising leads

New methods for the comprehensive analysis of bioactive compounds in Cannabis sativa L. (hemp)

Chemical Characterization and evaluation of the antibacterial activity of essential oils from fibre-type Cannabis sativa L. (Hemp)

Recent advances in the chemistry of hashish

Chemical constituents of marijuana: The complex mixture of natural cannabinoids

Isolation and characterization of new Cannabis constituents from a high potency variety

Non-cannabinoid constituents from a high potency Cannabis sativa variety

Raskin, I. The composition of Hemp seed oil and its potential as an important source of nutrition

phenolics, terpenes and alkaloids of Cannabis. Molecules

Constituents of Cannabis sativa L. XVII. A review of the natural constituents

Cannabinoids: Occurrence and medicinal chemistry

Bioactive chemical composition of Cannabis extracts and cannabinoid receptors

Constituents of Cannabis sativa

Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes

New bibenzyl cannabinoid from the New Zealand liverwort Radula marginata

Cannabigerol-ähnliche verbindungen aus Helichrysum umbraculigerum

A scoping review of the use of cannabidiol in psychiatric disorders

Cannabinoids, the endocannabinoid system, and pain: A review of preclinical studies

Cannabinoid signaling in health and disease. Can

Clinical approaches to Cannabis: A narrative review

From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology

Antioxidative and anti-inflammatory properties of cannabidiol

Minor cannabinoids: Biosynthesis, molecular pharmacology and potential therapeutic uses

Effects of endocannabinoid system modulation on cognitive and emotional behavior

The endocannabinoid system modulating levels of consciousness, emotions and likely dream contents

Cannabidiol drugs clinical trial outcomes and adverse effects

Medical use of cannabinoids

Cannabis for chronic pain: Challenges and considerations

Fourth generation of synthetic cannabinoid receptor agonists: A review on the latest insights

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Molecular characterization of a peripheral receptor for cannabinoids

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB 1 and CB 2

The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt

The CB 1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase

Mechanism of extracellular signal-regulated kinase activation by the CB 1 cannabinoid receptor

The CB 1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway

Cannabinoids promote oligodendrocyte progenitor survival: Involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling

Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways

Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenylylcyclase

CB 1 and CB 2 receptor pharmacology

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

2-Arachidonoylglycerol and the cannabinoid receptors

Cannabinoid receptors in the central nervous system: Their signaling and roles in disease

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-A short review

Cannabinoid receptor signaling in central regulation of feeding behavior: A mini-review

Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists

Selective activation of cannabinoid receptor 2 regulates Treg/Th17 balance to ameliorate neutrophilic asthma in mice

Modern approaches to the development of synthetic cannabinoid receptor probes

Beta-caryophyllene is a dietary cannabinoid

Cannabinoid 2 receptor agonist and L-arginine combination attenuates diabetic cardiomyopathy in rats via NF-kβ inhibition. Can

Antinociceptive and chondroprotective effects of prolonged β-caryophyllene treatment in the animal model of osteoarthritis: Focus on tolerance development

Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception

Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis

Anandamide and vanilloid TRPV1 receptors

The orphan receptor GPR55 is a novel cannabinoid receptor

Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells

Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: Mechanisms involved

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids

Cannabinoid receptors CB1 and CB2 form functional heteromers in brain

Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids

Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer

Adenosine A2A receptors enable the synaptic effects of cannabinoid CB1 receptors in the rodent striatum

AT1R-CB 1 R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II

Mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: Electrophysiological and FRET assay analysis

Functional interactions between endogenous cannabinoid and opioid systems: Focus on alcohol, genetics and drug-addicted behaviors

Heteromultimerization of cannabinoid CB 1 receptor and orexin OX 1 receptor generates a unique complex in which both protomers are regulated by orexin A

Cannabinoid Receptors and the endocannabinoid system: Signaling and function in the central nervous system

Cannabinoids and cannabinoid receptors: The story so far

Similarities and differences upon binding of naturally occurring ∆ 9 -tetrahydrocannabinol-derivatives to cannabinoid CB 1 and CB 2 receptors

Adverse health effects of marijuana use

A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: A focus on pharmacokinetic variability and pharmacodynamics

Tetrahydrocannabinol (THC)

Modulating the endocannabinoid system in human health and disease-Successes and failures

Review of available data for the efficacy and effectiveness of nabiximols oromucosal spray (Sativex ® ) in multiple sclerosis patients with moderate to severe spasticity

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

CBD activation of TRPV1 induces oxidative signaling and subsequent ER stress in breast cancer cell lines

Cannabidiol-Recent advances

Evidences for the anti-panic actions of cannabidiol

Cannabis sativa constituent, as an antipsychotic drug

Reasons for cannabidiol use: A cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo

Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

CBD) and its analogs: A review of their effects on inflammation

Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw

The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain

Cannabidiol modulation of oxidative stress and signalling

The therapeutic potential of Cannabis in counteracting oxidative stress and inflammation

Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer

Cannabidiol induces cell death in human lung cancer cells and cancer stem cells

Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy

Cannabinoids as anticancer therapeutic agents

Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes

Neuroprotective antioxidants from marijuana

Antioxidant and neuroprotective effects induced by cannabidiol and cannabigerol in rat CTX-TNA2 astrocytes and isolated cortexes

The role of cannabidiol (CBD) in chronic pain management: An Assessment of current evidence

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

Prospects for the use of cannabinoids in psychiatric disorders

Safety and side effects of cannabidiol, a Cannabis sativa constituent

Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome

A Phase I, Randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects

Molecular pharmacology of synthetic cannabinoids: Delineating CB1 receptor-mediated cell signaling

Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells

Cannabidiol arrests onset of autoimmune diabetes in NOD mice

Overcoming the bell-shaped dose-response of cannabidiol by using Cannabis extract enriched in cannabidiol

The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish

Identification of a new chemotype in Cannabis sativa: Cannabigerol-dominant plants, biogenetic and agronomic prospects

Biotechnological approaches on two high CBD and CBG Cannabis sativa L. (Cannabaceae) varieties: In vitro regeneration and phytochemical consistency evaluation of micropropagated plants using quantitative 1 H-NMR

Cannabigerol action at cannabinoid CB 1 and CB 2 receptors and at CB 1 -CB 2 heteroreceptor complexes

Evaluation of phytocannabinoids from high potency Cannabis sativa using in vitro bioassays to determine structure-activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes

Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist

Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid

Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8

The pharmacological case for cannabigerol

Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation

Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa

Phytocannabinoids as novel therapeutic agents in CNS disorders

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease

Biological activity of cannabichromene, its homologs and isomers

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action

The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis

Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice

The effect of cannabichromene on adult neural stem/progenitor cells

CB1R-dependent regulation of astrocyte physiology and astrocyte-neuron interactions

Cannabichromene, related phytocannabinoids, and 5-fluoro-cannabichromene have anticonvulsant properties in a mouse model of Dravet Syndrome

Cannabis-derived compounds cannabichromene and ∆ 9 -tetrahydrocannabinol interact and exhibit cytotoxic activity against urothelial cell carcinoma correlated with inhibition of cell migration and cytoskeleton organization

Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms

Pharmacological data of cannabidiol-and cannabigerol-type phytocannabinoids acting on cannabinoid CB 1 , CB 2 and CB 1 /CB 2 heteromer receptors

Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation

Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews

Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting

Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT 1A receptor-mediated suppression of nausea and anxiety in rats

Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis

Effect of cannabidiolic acid and ∆ 9 -tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain

Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet Syndrome

Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice

Effect of prior foot shock stress and ∆ 9 -tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats

Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

Efficacy of cannabinoids in a pre-clinical drug-screening platform for Alzheimer's disease

Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors. Free Radic

Anti-biofilm activity of cannabigerol against Streptococcus mutans. Microorganisms

Anti-bacterial properties of cannabigerol toward Streptococcus mutans

Ten Ham, M. Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol

Chemical investigation of Cannabis sativa leading to the discovery of a prenylspirodinone with anti-microbial potential

Cannabigerol prevents quorum sensing and biofilm formation of Vibrio harveyi. Front

Effect of the synthetic cannabinoid HU-210 on quorum sensing and on the production of quorum sensing-mediated virulence factors by Vibrio harveyi

Cannabidiol is a novel modulator of bacterial membrane vesicles

Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria

Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin

Anti-biofilm activity of cannabidiol against Candida albicans

Rapid Antibacterial activity of cannabichromenic acid against methicillin-resistant Staphylococcus aureus

Bacterial persister cell formation and dormancy

Persistence of antibiotic resistance in bacterial populations

Surviving as a community: Antibiotic tolerance and persistence in bacterial biofilms

Antibiotic resistance: A rundown of a global crisis

Antibiotics versus biofilm: An emerging battleground in microbial communities

Tolerance and resistance of microbial biofilms

Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: A preliminary observation

Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?

Bacterial exo-polysaccharides in biofilms: Role in antimicrobial resistance and treatments

Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches

Cannabinoids block cellular entry of SARS-CoV-2 and the emerging variants

Louria-Hayon, I. The immunopathology of COVID-19 and the Cannabis paradigm

Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE Study): A randomized, double-blind, placebo-controlled clinical trial

Cannabinoids and viral infections

COVID-19 pandemic, substance use disorders and body image issues, a worrisome correlation

The COVID-19 cannabis health study: Results from an epidemiologic assessment of adults who use cannabis for medicinal reasons in the United States

Genetic liability to Cannabis use disorder and COVID-19 hospitalization

In silico repositioning of cannabigerol as a novel inhibitor of the enoyl acyl carrier protein (ACP) reductase (InhA)

Types and origins of bacterial membrane vesicles

Bacterial quorum sensing in complex and dynamically changing environments

Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

The cannabinoid system and immune modulation

Cannabinoid receptors and endocannabinoids: Evidence for new players

The endocannabinoid system may modulate sleep disorders in aging

Endocannabinoid system dysfunction in mood and related disorders

Reviewing the role of the endocannabinoid system in the pathophysiology of depression

The interplay between the immune and the endocannabinoid systems in cancer

Roles of endocannabinoids and endocannabinoid-like molecules in energy homeostasis and metabolic regulation: A nutritional perspective

Neuromodulatory functions of the endocannabinoid system

Endocannabinoids-At the crossroads between the gut microbiota and host metabolism

Therapeutic attributes of endocannabinoid system against neuro-inflammatory autoimmune disorders

Characterization of endocannabinoid-mediated induction of myeloidderived suppressor cells involving mast cells and MCP-1

Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation

Endocannabinoids and immune regulation

Production of endocannabinoids by activated T cells and B cells modulates inflammation associated with delayed-type hypersensitivity

Endocannabinoids in immune regulation and immunopathologies

Galve-Roperh, I. The endocannabinoid system drives neural progenitor proliferation

Endocannabinoid signalling in stem cells and cerebral organoids drives differentiation to deep layer projection neurons via CB 1 receptors

Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: Role of vanilloid receptors and lipoxygenases

Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation

Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice

An Introduction to the endogenous cannabinoid system

The gut microbiome, endocannabinoids and metabolic disorders

Neurotransmission: Emerging roles of endocannabinoids

Endocannabinoid-mediated synaptic plasticity in the CNS

Mechanisms of CB1 receptor signaling: Endocannabinoid modulation of synaptic strength

Endocannabinoid signaling and long-term synaptic plasticity

A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization

The Epac-phospholipase Cε pathway regulates endocannabinoid signaling and cocaine-induced disinhibition of ventral tegmental area dopamine neurons

Phospholipase Cγ2 regulates endocannabinoid and eicosanoid networks in innate immune cells

Biosynthetic pathways of the endocannabinoid anandamide

Endocannabinoids in the central nervous system-An overview

A second endogenous cannabinoid that modulates long-term potentiation

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat

Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors

New approaches and challenges to targeting the endocannabinoid system

Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system

Endocannabinoids drive the acquisition of an alternative phenotype in microglia

Simultaneous measurement of three N-acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry

Circulating endocannabinoids: From whence do they come and where are they going? Neuropsychopharmacology

Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells

Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of plateletactivating factor

Astrocytes in culture produce anandamide and other acylethanolamides

Contributions of endocannabinoid signaling to psychiatric disorders in humans: Genetic and biochemical evidence

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction

Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide

Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist

2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain

TRPV1 activation by anandamide via a unique lipid pathway

A closer look at anandamide interaction with TRPV1. Front. Mol

Endocannabinoid activation of the TRPV1 ion channel is distinct from activation by capsaicin

Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs

The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice

The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer

A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: Enantioselectivity and effects at other TRP channels and in sensory neurons

Cannabinoids and the expanded endocannabinoid system in neurological disorders

Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide

N-arachidonoyl dopamine modulates acute systemic inflammation via nonhematopoietic TRPV1

The endocannabinoid/endovanilloid system and depression

Neuroprotective and immunomodulatory action of the endocannabinoid system under neuroinflammation

Potassium channels as molecular targets of endocannabinoids

Endocannabinoids: Getting the message across

Endocannabinoid-mediated short-term synaptic plasticity: Depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE)

Synaptic functions of endocannabinoid signaling in health and disease

Endocannabinoid-mediated control of synaptic transmission

Anandamide Revisited: How cholesterol and ceramides control receptor-dependent and receptor-independent signal transmission pathways of a lipid neurotransmitter

The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent

Ceramide binding to anandamide increases its half-life and potentiates its cytotoxicity in human neuroblastoma cells

Fatty acid incorporation is decreased in astrocytes cultured from alpha-synuclein gene-ablated mice

Identification of intracellular carriers for the endocannabinoid anandamide

Emerging role of neuronal exosomes in the central nervous system

The emerging role of neural cell-derived exosomes in intercellular communication in health and neurodegenerative diseases

Active endocannabinoids are secreted on extracellular membrane vesicles

Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism

Endocannabinoid signaling in microglial cells

Endocannabinoids mediate neuron-astrocyte communication

Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα

Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human gut in vitro and in vivo-A randomized, placebo-controlled, double-blind controlled trial

Endocannabinoids, related compounds and their metabolic routes

Microglia produce and hydrolyze palmitoylethanolamide

Receptor-dependent formation of endogenous cannabinoids in cortical neurons

Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α

Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator

Palmitoylethanolamide: A potential alternative to cannabidiol

Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis

Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent

Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: Efficacy and safety in sciatic pain and carpal tunnel syndrome

Control of pain initiation by endogenous cannabinoids

Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide

Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance

De Petrocellis, L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells

Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: Involvement of the CB2 receptor

The nuclear receptor peroxisome proliferatoractivated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide

A fatty gut feeling

The lipid messenger OEA links dietary fat intake to satiety

Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats

The role of a bioactive lipid amide in modulating eating behaviour

The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55

An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors

N-acyl-dopamines: Novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo

Anti-inflammatory dopamine-and serotoninbased endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel

A novel endocannabinoid and endovanilloid with widespread physiological and pharmacological activities. Cannabis Cannabinoid Res

N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia

Effect of N-arachidonoyl-L-serine on human cerebromicrovascular endothelium

N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties

Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator

N-arachidonoyl-Lserine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury

Anandamide prevents the adhesion of filamentous Candida albicans to cervical epithelial cells

Growth effects of N-Acylethanolamines on gut bacteria reflect altered bacterial abundances in inflammatory bowel disease

Bacterial persistence as a phenotypic switch

Robust, linear correlations between growth rates and β-lactammediated lysis rates

Impact of FtsZ inhibition on the localization of the penicillin binding proteins in methicillin-resistant Staphylococcus aureus

How Staphylococcus aureus biofilms develop their characteristic structure

Functional amyloids composed of phenol soluble modulins stabilize Staphylococcus aureus biofilms

Extracellular DNA facilitates the formation of functional amyloids in Staphylococcus aureus biofilms

Gut-brain axis: Role of lipids in the regulation of inflammation, pain and CNS diseases

Rapid and concomitant gut microbiota and endocannabinoidome response to diet-induced obesity in mice

Wh)olistic (E)ndocannabinoidome-Microbiome-Axis modulation through (N)utrition (WHEN) to curb obesity and related disorders

Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract

The endocannabinoid system: A bridge between Alzheimer's disease and gut microbiota

At the heart of microbial conversations: Endocannabinoids and the microbiome in cardiometabolic risk

Aberrant intestinal microbiota in individuals with prediabetes

The neuroactive potential of the human gut microbiota in quality of life and depression

A comprehensive review on the role of the gut microbiome in human neurological disorders

Gut bacteria and neuropsychiatric disorders. Microorganisms

The role of the gut microbiome in the development of schizophrenia

Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 2016, 4, 30

Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort

Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system

Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice

Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

Harnessing the anti-inflammatory potential of palmitoylethanolamide

Is there a role for palmitoylethanolamide in the treatment of depression

Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses

Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain

Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms

Endocannabinoid anandamide attenuates acute respiratory distress syndrome through modulation of microbiome in the gut-lung axis

The endocannabinoid system links gut microbiota to adipogenesis

The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome

Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans

The gastrointestinal pharmacology of cannabinoids: Focus on motility

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity

Anti-inflammatory effect of palmitoylethanolamide on human adipocytes

Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages

Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes

Endocannabinoids in the gut

Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity

A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis

Rimonabant potentiates the antifungal activity of amphotericin B by increasing cellular oxidative stress and cell membrane permeability

N-Docosahexaenoylethanolamine: A neurotrophic and neuroprotective metabolite of docosahexaenoic acid

Oleoylethanolamide treatment affects gut microbiota composition and the expression of intestinal cytokines in Peyer's patches of mice

Endocannabinoid system as a promising therapeutic target in inflammatory bowel disease-A systematic review

Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation

Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide

Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation

Targeting endocannabinoid degradation protects against experimental colitis in mice: Involvement of CB1 and CB2 receptors

The gut microbiota, bacterial metabolites and colorectal cancer

The antiinflammatory effect of bacterial short chain fatty acids is partially mediated by endocannabinoids

Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells

Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections

Prophylactic palmitoylethanolamide prolongs survival and decreases detrimental inflammation in aged mice with bacterial meningitis

Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases

Gut microbiome structure and metabolic activity in inflammatory bowel disease

Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism

Interference in bacterial quorum sensing: A biopharmaceutical perspective